HCWB Soars 500% in a Week on CAR-T Buzz and a One-Time Deal — But Can a Company Running on Fumes Sustain It?
Shares of HCW Biologics slipped 13.2% in pre-market to $2.11 on May 21, cooling after an extraordinary rally that took the stock from $0.34 to $2.43 in just six trading sessions. No new catalyst emerged overnight — this looks like textbook profit-taking after one of the wildest runs in micro-cap biotech this year.
• A Single Licensing Deal Powered Nearly All the Revenue
HCWB reported Q1 2026 revenue of $6.54 million and net income of $3.47 million , a stunning reversal from just $5,065 in the year-ago quarter . But virtually all of it came from one source: a $6.5 million licensing fee from Beijing Trimmune Biotech . The deal delivered $3.5 million in upfront cash plus a minority equity stake in Trimmune valued at another $3.5 million . Strip out that deal, and there is almost no recurring revenue — meaning the "earnings beat" is essentially non-repeatable without another partnership.
• CAR-T Research Is Promising but Purely Preclinical
A Science Advances publication showed HCWB's compound generates CAR-T cells — cancer-fighting immune cells engineered in a lab — enriched with ≥50% long-lived memory stem cells, outperforming standard manufacturing methods in animal models of leukemia and HIV . That's scientifically significant, but these findings are preclinical — years and hundreds of millions of dollars from commercial reality.
• The Company Itself Warns It May Not Survive
Management discloses cumulative net losses of $102.3 million, cash of just $1.23 million, and explicitly states substantial doubt about its ability to continue as a going concern — accounting language meaning the company may not be able to pay its bills over the next 12 months. Current liabilities stand at $19.96 million against that tiny cash balance.
• Nasdaq Delisting Risk Looms Over Every Gain
HCWB secured an appeal hearing on May 5 to contest a Nasdaq delisting notice for failing the exchange's $1.00 minimum share-price rule . The decision remains outstanding . Ironically, the rally itself may temporarily resolve the price issue — but if shares drift back below a dollar, the listing threat returns.
The bottom line: investors are pricing in hope — a potential CAR-T partnership, a successful clinical trial readout due Q4 2026, and continued exchange listing. Each of those outcomes is uncertain, and the company has $1.23 million in cash to get there.